Dong-A Socio Holdings will merge its wholly owned subsidiary, Dong-A Pharmaceutical, by absorption and transition from a pure holding company structure to an operating holding company structure.
On July 23, Dong-A Socio Holdings announced that it will merge Dong-A Pharmaceutical by absorption on October 1. This merger will be carried out as a small-scale merger without issuing new shares.
Since no new shares will be issued, there will be no change in the shareholder structure or equity ratio of Dong-A Socio Holdings after the merger.
The company explained that, through this merger, it plans to internalize Dong-A Pharmaceutical’s stable cash generation capabilities and core business competitiveness directly, transitioning from a pure holding company to an operating holding company structure.
Additionally, the company expects to strengthen responsible management by focusing the group’s resources on its core businesses and unifying the decision-making system through the board of directors and management of the surviving entity, Dong-A Socio Holdings.
The company also expects that the merger with Dong-A Pharmaceutical will resolve market concerns over overlapping listings of major subsidiaries, thereby aiding a revaluation of its corporate value.
A representative from Dong-A Socio Holdings stated, “This small-scale merger is a strategic decision to continue the success of the holding company transition initiated in 2013 and to further establish the company as a leader in the global healthcare market.”
Hot Picks Today
Dong-A Socio Holdings will pursue both a transition to an operating holding company structure and the enhancement of management efficiency and corporate value through the absorption of Dong-A Pharmaceutical.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.